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Abstract Platelet-derived growth factor (PDGF) exerts its 
effects on cells via binding to structurally similar a- and P-
tyrosine kinase receptors. Ligand binding induces receptor 
dimerization and autophosphorylation which allows docking of 
SH2 domain containing signal transduction molecules. At least 
10 different SH2 domain molecules bind in a specific manner to 
11 identified autophosphorylated tyrosine residues in the PDGF 
P-receptor, thereby initiating signaling pathways leading to cell 
growth and motility. Available information indicates that there is 
considerable cross-talk between different signaling pathways, 
and that stimulatory and inhibitory signals often are initiated in 
parallel. 
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1. Introduction 
Platelet-derived growth factor (PDGF) is a family of signal-
ing molecules of particular importance for growth and motil-
ity of connective tissue cells (reviewed in [1,2]). Structurally, 
PDGF isoforms are disulfide-bonded dimers of homologous 
A- and B-polypeptide chains, arranged as homodimers 
(PDGF-AA and PDGF-BB) or a heterodimer (PDGF-AB). 
PDGF isoforms have important functions during the embry-
onal development. Mice with the B-chain gene inactivated 
show a striking deficiency of mesangial cells of the kidney 
glomeruli leading to a defect filtration [3]. PDGF A-chain 
gene knock-out resulted in generalized lung emphysema due 
to a lack of alveolar myofibroblasts [4]. In the adult, PDGF 
stimulates wound healing [5], and overactivity of PDGF is 
sometimes associated with tumorigenesis and fibrotic disease 
(reviewed in [1]). These findings are consistent with an impor-
tant function of PDGF in connective tissue development. 
PDGF isoforms exert their effects on target cells by binding 
to two structurally related protein tyrosine kinase receptors. 
The oc-receptor binds both the A- and B-chains of PDGF, 
whereas the P-receptor binds only the B-chain; since the 
ligand is bivalent, the different PDGF isoforms induce specific 
dimeric complexes of PDGF receptors. Both a- and P-recep-
tors induce mitogenic responses. Both receptors also stimulate 
actin reorganization in the form of edge ruffling and loss of 
stress fibers; the p-receptor, but not the oc-receptor, in addi-
tion stimulates the formation of circular ruffles on the dorsal 
surface of the cell. Moreover, whereas the P-receptor mediates 
stimulation of chemotaxis, the a-receptor does not; in fact the 
a-receptor inhibits the chemotaxis of certain cell types (re-
viewed in [1]). The present review focuses on the intracellular 
signal transduction pathways that are involved in PDGF-in-
duced cell growth and motility, and will discuss the fact that 
often stimulatory and inhibitory pathways are induced in par-
allel. 
2. Activation of PDGF receptors 
Receptor dimerization is an important event in signal trans-
duction via PDGF receptors, as is the case for most if not all 
tyrosine kinase receptors [6]. The juxtaposition of the kinase 
domains of two receptors allows phosphorylation in trans be-
tween the receptors, often referred to as autophosphorylation. 
The autophosphorylation serves two important functions: it 
increases the catalytic activity of the kinase and it provides 
docking sites for downstream signal transduction molecules. 
The known autophosphorylated tyrosine residues in the p-
receptor for PDGF are illustrated in Fig. 1. One site is a 
conserved tyrosine residue localized inside the kinase domain 
(Tyr857). Mutation of this residue to a phenylalanine residue 
gives a receptor with a lowered kinase activity, suggesting that 
phosphorylation of Tyr857 is important for activation of the 
kinase [7]. The other autophosphorylation sites are spread out 
over the cytoplasmic part of the receptor; a total of 11 of the 
15 tyrosine residues in the noncatalytic part of the receptor 
are phosphorylated (reviewed in [8]; Ronnstrand et al., un-
published observations). Also the a-receptor becomes phos-
phorylated on several tyrosine residues, but the mapping data 
are less complete for this receptor. 
3. Interaction between the activated PDGF P-receptor and SH2 
domain proteins 
An important aspect of signal transduction is regulated 
protein-protein interactions between components in the differ-
ent signaling pathways. Such interactions are directed by dif-
ferent types of domains, e.g. SH2 and PTB domains which 
recognize phosphorylated tyrosine residues in specific environ-
ments (reviewed in [9]). At least 10 different SH2 domain 
containing molecules bind to different phosphorylated tyro-
sine residues in the PDGF P-receptor in a specific manner 
(Fig. 1); the specificity is primarily determined by the charac-
ter of the 3-6 amino acid residues downstream of the phos-
phorylated tyrosine. No PTB domain is known to bind to the 
receptor. The SH2 domain proteins that interact with the 
PDGF P-receptor fall into two categories, i.e. molecules 
with enzymatic or other activity, and adaptor molecules which 
serve to connect the receptor with other molecules. 
One class of molecules that bind to the receptor are them-
selves tyrosine kinases, i.e. members of the Src family, which 
bind to phosphorylated Tyr579, and with lower affinity to 
Tyr081, in the juxtamembrane domain [10]. The binding leads 
to activation of the Src kinase, after which Src phosphorylates 
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Fig. 1. Schematic illustration of the interaction between the autophosphorylated PDGF p-receptor and downstream signal transduction mole-
cules. A ligand-induced dimeric receptor complex is shown. Ig-like domains in the extracellular part are illustrated by filled circles. Tyr857 inside 
the C-terminal part of the kinase domain (filled rectangles) is indicated, as well as the numbers of all intracellular tyrosine residues outside the 
catalytic domain; tyrosine residues known to be autophosphorylated are indicated with P. The specificity in the interaction between SH2 do-
main molecules and autophosphorylated tyrosine residues is indicated; solid lines indicate high affinity interactions and broken lines interactions 
of lower affinity. Note that it is not known how many SH2 domain proteins that can bind to the receptor dimer simultaneously. 
the PDGF receptor (see further below), as well as other sub-
strates. Members of the Src family have important roles in 
PDGF-induced mitogenicity [11], but the exact mechanism for 
their involvement remains to be elucidated. 
An important signaling molecule, which binds to the PDGF 
P-receptor, is phosphatidylinositol 3'-kinase (PI 3'-kinase). 
The regulatory subunit, p85, binds to phosphorylated Tyr740 
or Tyr751 in the kinase insert of the receptor [12,13]. Hereby, 
the activity of the catalytic subunit, pi 10, increases, leading to 
the phosphorylation of phosphatidylinositol(4,5)bisphosphate 
(PI(4,5)P2) to PI(3,4,5)P3. The downstream effectors of PI 3'-
kinase include the serine/threonine kinase Akt, certain mem-
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Fig. 2. Schematic illustration of signaling pathways downstream of 
the PDGF P-receptor that are important for cell growth and chemo-
taxis. Stimulatory (-») and inhibitory (—l) pathways are indicated 
with solid lines. Accessory pathways are indicated with broken lines. 
bers of the protein kinase C (PKC) family, as well as the small 
GTP binding proteins Rho, Rac and Ras (reviewed in [14]). 
Studies of tyrosine to phenylalanine mutants of the PDGF p-
receptor which have been rendered specifically unable to acti-
vate the PI 3'-kinase, as well as studies using wortmannin and 
other PI 3'-kinase inhibitors, have indicated that PI 3'-kinase 
has an important role in signaling pathways leading to chemo-
taxis and actin reorganization [15,16], and in certain cell types 
it is also of importance for other PDGF responses, including 
cell growth [12,13]. 
Phospholipase C-y (PLC-y) is an enzyme which also uses 
PI(4,5)P2 as substrate, and cleaves it into inositoltrisphos-
phate which mobilizes Ca2+ from intracellular stores and di-
acylglycerol which activates members of the PKC family. 
PLC-y binds to phosphorylated Tyr1021 and, with lower affin-
ity, Tyr1009, in the C-terminal tail of the PDGF |3-receptor 
[17]. This leads to tyrosine phosphorylation of PLC-y, which 
increases its catalytic activity. Mutation of Tyr1021 to a phen-
ylalanine residue, which leads to an inability of the mutant 
receptor to phosphorylate and activate PLC-y, has no dramat-
ic effect on signaling via the PDGF P-receptor. However, 
when signaling from the receptor is severely compromised 
by mutation of several tyrosine residues, reintroduction of 
Tyr1021, and thereby of the ability to activate PLC-y, is asso-
ciated with reappearance of some mitogenic signaling [18]. 
Moreover, PLC-y has been shown under certain circumstances 
to be involved also in chemotactic signaling [19,20]. 
Another SH2 domain molecule which binds to the C-termi-
nal tail of the |3-receptor is SHP-2, a protein tyrosine phos-
phatase which binds to phosphorylated Tyr1009 [21]. The in-
teraction leads to activation of the enzymatic activity with 
potential ability to dephosphorylate the autophosphorylated 
receptors. 
Activation of the small GTP binding protein Ras is an 
important event in PDGF signaling. Ras is converted to the 
GTP-bound form, and thereby activated, by the nucleotide 
exchange factor Sosl which forms a complex with the SH2 
domain containing adaptor molecule Grb2. The activating 
event is the translocation of the Grb2/Sosl complex to the 
inside of the cell membrane, where Ras is located, through 
direct binding to the PDGF P-receptor to phosphorylated 
Tyr716 [22], or indirectly via the adaptor She [23] or the tyro-
sine phosphatase SHP-2 [24], which are both phosphorylated 
on tyrosine residues by the PDGF receptor. The downstream 
activators of Ras include the MAP kinase cascade which is 
important in PDGF-mediated stimulation of cell growth 
[25,26]. 
Ras is deactivated when the bound GTP is dephospho-
rylated to GDP, a process which is catalyzed by the GTPase 
activating protein (GAP) of Ras. GAP binds to phospho-
rylated Tyr771 of the PDGF P-receptor [12,13], an interaction 
which potentially regulates Ras activation. 
Signal transducers and activators of transcription (STATs) 
are of particular importance for signaling via cytokine recep-
tors (reviewed in [27]). However, certain STAT members are 
also phosphorylated and activated by PDGF receptors [28]. 
They interact with phosphorylated Tyr579, Tyr581 and Tyr775 
[29], but their significance in PDGF signaling remains to be 
determined. 
Grb2 and p85 of PI 3'-kinase are two adaptor molecules 
with well characterized binding partners, i.e. Sosl and pi 10, 
respectively. However, a number of other adaptor molecules, 
for which the interactive partners are less well known, also 
bind to the PDGF P-receptor. These include Nek which binds 
to phosphorylated Tyr751 [30], She which binds with rather 
low affinity to several of the autophosphorylated tyrosine res-
idues in the receptor [31], and Grb7 which is structurally 
related to Grb2 and binds to phosphorylated Tyr775 [32]. 
4. Cross-talk between signaling pathways leading to cell growth 
and chemotaxis 
The available information regarding the involvement of dif-
ferent signaling pathways downstream of PDGF P-receptors 
in stimulation of cell growth and chemotaxis is summarized in 
Fig. 2. As discussed above, activation of Ras, via direct or 
indirect binding of the Grb2/Sosl complex to the receptor is 
important for stimulation of cell growth [25,26]. Src is also 
important for stimulation of cell growth in a pathway involv-
ing the transcription factor c-Myc [33]. Activation of PI 3'-
kinase is of major importance for stimulation of chemotaxis, 
presumably via activation of Rac or other small GTP binding 
proteins [34]. PLC-y appears not to be of major importance 
for signaling cell growth or chemotaxis, but may in certain 
situations stimulate both cell growth [18] and chemotaxis 
[19,20], presumably via activation of PKC or increase in the 
cytoplasmic Ca2+ concentration. 
Recent studies have given several examples of cross-talk 
between different signaling pathways. For instance, a direct 
physical interaction between Ras and PI 3'-kinase has been 
demonstrated as well as activation of PI 3'-kinase by Ras [35]. 
Certain PI 3'-kinase responses have also been shown to be 
mediated by Ras [36]. Moreover, the small GTP binding pro-
teins Ras, Rho and Rac have been shown to activate each 
other [37-39]. Such cross-talk may be the reason why Ras 
activation induces not only cell proliferation, but also under 
certain conditions chemotaxis [40], and may also explain why 
PI 3'-kinase in addition to its major role in stimulation of 
actin reorganization and chemotaxis also in some cell types 
stimulates cell growth [12,13]. 
5. Stimulatory and inhibitory signals for cell growth and 
chemotaxis 
An interesting observation is that activation of PDGF re-
ceptors often appears to induce stimulatory and inhibitory 
signals for cell growth as well as motility in parallel. Some 
examples will be discussed below. 
The tyrosine phosphatase SHP-2 binds to activated and 
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autophosphorylated PDGF receptors, an interaction which 
increases the phosphatase activity of SHP-2 [41]. Moreover, 
it has been shown that the autophosphorylated receptor is a 
substrate for SHP-2 [42]. Thus, it is an interesting possibility, 
which remains to be elucidated, that the recruitment of SHP-2 
to the autophosphorylated PDGF receptors serves a feedback 
control function leading to a dephosphorylation of the recep-
tor and thus a decreased interaction with other SH2 domain 
proteins. It should be noted that SHP-2 may also be involved 
in stimulatory pathways [24]. 
Another, more specific, feedback mechanism could be ex-
erted by GAP. Ras is localized at the cell membrane and is 
activated after translocation of the Grb2/Sosl complex to the 
autophosphorylated PDGF P-receptor. The juxtaposition at 
the receptor of GAP which deactivates Ras could serve as a 
feedback control mechanism; however, this possibility needs 
to be experimentally verified. Interestingly, GAP binds to the 
p-receptor but not to the a-receptor [43], and this may be one 
explanation for the differences in signaling between the two 
receptors. 
Binding of members of the Src family of tyrosine kinases to 
the juxtamembrane domain of the PDGF P-receptor leads to 
their activation [10]. The Src kinase then phosphorylates the 
receptor on Tyr934 located within the C-terminal part of the 
kinase domain [19], as well as other substrates. Mutation of 
Tyr934 to a phenylalanine gives a receptor with decreased abil-
ity to mediate cell growth, but an increased ability to mediate 
cell motility [19]. This finding is consistent with the notion 
that Src phosphorylation of Tyr934 is important for stimula-
tion of cell growth, and also suggests that this phosphoryla-
tion exerts a negative effect on motility signals. 
In contrast to the P-receptor, the a-receptor for PDGF 
inhibits chemotaxis induced by other agents, e.g. in human 
fibroblasts [44], smooth muscle cells [45], and transfected 
PAE cells [46]. PI 3'-kinase, which has been shown to have 
an important role in stimulation of chemotaxis by the P-re-
ceptor, also binds to the a-receptor [47]. Yokote et al. [46] 
explored the possibility that inhibitory signals also are initi-
ated after activation of the a-receptor. Analysis of a series of 
tyrosine to phenylalanine residue mutants revealed three that 
were able to stimulate chemotaxis, i.e. receptor mutants in 
which Tyr768, Tyr993 or Tyr1018 were replaced with phenylala-
nine residues. Tyr768 and Tyr1018 are autophosphorylation 
sites, which then may serve as docking sites for molecules 
which inhibit chemotaxis. Tyr993 is not autophosphorylated, 
but its mutation leads to an increased phosphorylation of the 
neighboring Tyr988, which may be involved in stimulation of 
chemotaxis. 
6. Concluding remarks 
Research during the recent years has revealed several signal 
transduction pathways that are activated by PDGF. However, 
the information about the importance of individual pathways 
in PDGF-stimulated cell growth and motility is still incom-
plete. Two striking general principles have appeared from 
these studies so far: there is considerable cross-talk between 
individual pathways, and often stimulatory signals are initi-
ated in parallel to inhibitory ones. This organization of intra-
cellular signal transduction allows modulation and fine tun-
ing. Since individual signal transduction molecules may be 
present at different amounts in different cell types, another 
consequence is that PDGF stimulation may give different ef-
fects in different PDGF responsive cell types. 
Acknowledgements: I thank Arne Ostman and Lars Ronnstrand for 
valuable comments, and Ingegard Schiller for help in the preparation 
of the manuscript. 
References 
[4] 
[5: 
[& 
v. 
[s: 
[9 
[iff 
[ii 
[12: 
[i3: 
[14 
[is: 
[ie: 
[17 
[is: 
[is: 
[20] 
[21 
[22 
[23: 
[24] 
[25 
[26] 
[27 
[28: 
[2? 
[30] 
[31 
Heldin C-H, Westermark B. In : Clark R A F , editor. The Molec-
ular and Cellular Biology of Wound Repair. New York : Plenum 
Press, 1996:249-273. 
Raines EW, Bowen-Pope D F , Ross R. In: Sporn M B , Roberts 
AB, editors. Handbook of Experimental Pharmacology. Peptide 
Growth Factors and Their Receptors, Vol. 95, Part I. Heidel-
berg: Springer-Verlag, 1990:173-262. 
Leveen, P., Pekny, M., Gebre-Medhin, S., Swolin, B., Larsson, E. 
and Betsholtz, C. (1994) Genes Dev 8, 1875-1887. 
Bostrom, H. et al. (1996) Cell 85, 863-873. 
Robson, M.C., Phillips, L.G., Thomason, A., Robson, L.E. and 
Pierce, G.F. (1992) Lancet 339, 23-25. 
Heldin, C.-H. and Ostman, A. (1996) Cytokines Growth Factor 
Rev 7, 3-10. 
Fantl , W.J., Escobedo, J.A. and Williams, L.T. (1989) Mol Cell 
Biol 9, 4473^1478. 
Claesson-Welsh, L. (1994) J Biol Chem 269, 32023-32026. 
Pawson, T. (1995) Nature 373, 573-580. 
Mori , S., Ronnstrand, L., Yokote, K., Engstrom, A., Court-
neidge, S.A., Claesson-Welsh, L. and Heldin, C.-H. (1993) 
E M B O J 12, 2257-2264. 
Twamley-Stein, G.M., Pepperkok, R., Ansorge, W. and Court-
neidge, S.A. (1993) Proc Nat l Acad Sci USA 90, 7696-7700. 
Kazlauskas, A., Kashishian, A., Cooper, J.A. and Valius, M. 
(1992) Mol Cell Biol 12, 2534-2544. 
Fantl , W.J., Escobedo, J.A., Mart in , G.A., Turck, C.W., del 
Rosario, M., McCormick, F . and Williams, L.T. (1992) Cell 
69, 413^123. 
Panayotou G. In: Heldin C-H, Purton M, editors. Modular 
Texts in Molecular and Cell Biology: Signal Transduction, Vol. 
1. London: Chapman and Hall, 1996:189-204. 
Wennstrom, S., Siegbahn, A., Yokote , K., Arvidsson, A.-K., 
Heldin, C.-H., Mori , S. and Claesson-Welsh, L. (1994) Oncogene 
9, 651-660. 
Wennstrom, S. et al. (1994) Curr Biol 4, 385-393. 
Ronnstrand, L., Mori , S., Arvidsson, A.-K., Eriksson, A., Wern-
stedt, C , Hellman, U., Claesson-Welsh, L. and Heldin, C.-H. 
(1992) E M B O J 11, 3911-3919. 
Valius, M. and Kazlauskas, A. (1993) Cell 73, 321-334. 
Hansen, K., Johnell, M., Siegbahn, A., Rorsman, C , Engstrom, 
U., Wernstedt, C , Heldin, C.-H. and Ronnst rand, L. (1996) 
E M B O J 15, 5299-5313. 
Kundra , V., Escobedo, J.A., Kazlauskas, A., Kim, H.K., Rhee, 
S.G., Williams, L.T. and Zetter, B.R. (1994) Nature 367, 4 7 4 -
476. 
Valius, M., Bazenet, C. and Kazlauskas, A. (1993) Mol Cell Biol 
13, 133-143. 
Arvidsson, A.-K. et al. (1994) Mol Cell Biol 14, 6715-6726. 
Salcini, A.E., McGlade, J., Pelicci, G., Nicoletti, I., Pawson, T. 
and Pelicci, P.G. (1994) Oncogene 9, 2827-2836. 
Li, W., Nishimura, R., Kashishian, A., Batzer, A.G., Kim, 
W.J.H. , Cooper, J.A. and Schlessinger, J. (1994) Mol Cell Biol 
14, 509-517. 
Marshall , C.J. (1994) Curr Genet Dev 4, 82-89. 
Mulcahy, L.S., Smith, M.R. and Stacey, D.W. (1985) Nature 
313, 241-243. 
Ihle, J .N. (1995) Nature 377, 591-594. 
Silvennoinen, O., Schindler, C , Schlessinger, J. and Levy, D.E. 
(1993) Science 261, 1736-1739. 
S. Valgeirsdottir, K. Paukku, O. Silvennoinen, C-H. Heldin, L. 
Claesson-Welsh, J. Biol. Chem. (1997), submitted for publication. 
Nishimura, R., Li, W., Kashishian, A., Mondino , A., Zhou, M., 
Cooper, J. and Schlessinger, J. (1993) Mol Cell Biol 13, 6889-
6896. 
Yokote, K., Mori , S., Hansen, K., McGlade, J., Pawson, T., 
C.-H. HeldinlFEBS Letters 410 (1997) 17-21 21 
Heldin, C.-H. and Claesson-Welsh, L. (1994) J Biol Chem 269, 
15337-15343. 
[32] Yokote, K., Margolis, B., Heldin, C.-H. and Claesson-Welsh, L. 
(1996) J Biol Chem 271, 30942-30949. 
[33] Barone, M.V. and Courtneidge, S.A. (1995) Nature 378, 509-512. 
[34] Hawkins, P.T. et al. (1995) Curr Biol 5, 393-403. 
[35] Rodriguez-Viciana, P., Warne, P.H., Dhand, R., Vanhaese-
broeck, B., Gout, I., Fry, M.J., Waterfield, M.D. and Down-
ward, J. (1994) Nature 370, 527-532. 
[36] Hu, Q., Klippel, A., Muslin, A.J., Fantl, W.J. and Williams, L.T. 
(1995) Science 268, 100-102. 
[37] Olson, M.F., Ashworth, A. and Hall, A. (1995) Science 269, 
1270-1272. 
[38] Qiu, R.-G., Chen, J., Kirn, D., McCormick, F. and Symons, M. 
(1995) Nature 374, 457-459. 
[39] Khosravi-Far, R., Solski, P.A., Clark, G.J., Kinch, M.S. and 
Der, C.J. (1995) Mol Cell Biol 15, 6443-6453. 
[40] Kundra, V., Anand-Apte, B., Feig, L.A. and Zetter, B.R. (1995) 
J Cell Biol 130, 725-731. 
[41] Lechleider, R.J., Sugimoto, S., Bennett, A.M., Kashishian, A.S., 
Cooper, J.A., Shoelson, S.E., Walsh, C.T. and Neel, B.G. (1993) 
J Biol Chem 268, 21478-21481. 
[42] Klinghoffer, R.A. and Kazlauskas, A. (1995) J Biol Chem 270, 
22208-22217. 
[43] Heidaran, M.A., Beeler, J.F., Yu, J.-C, Ishibashi, T., LaRo-
chelle, W.J., Pierce, J.H. and Aaronson, S.A. (1993) J Biol 
Chem 268, 9287-9295. 
[44] Siegbahn, A., Hammacher, A., Westermark, B. and Heldin, 
C.-H. (1990) J Clin Invest 85, 916-920. 
[45] Koyama, N., Morisaki, N., Saito, Y. and Yoshida, S. (1992) 
J Biol Chem 267, 22806-22812. 
[46] Yokote, K., Mori, S., Siegbahn, A., Ronnstrand, L., Wernstedt, 
C , Heldin, C.-H. and Claesson-Welsh, L. (1996) J Biol Chem 
271, 5101-5111. 
[47] Yu, J.-C, Heidaran, M.A., Pierce, J.H., Gutkind, J.S., Lombar-
di, D., Ruggiero, M. and Aaronson, S.A. (1991) Mol Cell Biol 
11, 3780-3785. 
